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Introduction: Although dabigatran, a novel oral anti-coagulant, has been approved for the prevention of
thromboembolism in patients with non-valvular atrial fibrillation, the efficacy of dabigatran for the resolution of
established intra-cardiac thrombi has not been validated. Herein is describe a case in which dabigatran was
effective for thrombus resolution in a patient with a left ventricular aneurysm.
Case presentation: A 59-year-old Japanese man with a mid-ventricular obstructive hypertrophic
cardiomyopathy-associated apical aneurysm presented with a left ventricular apical thrombus (15.0mm×17.0mm).
Anti-coagulation therapy with dabigatran (150mg b.i.d. with meals) was initiated. Following dabigatran administration,
weekly echocardiographic examinations demonstrated gradual decreases in thrombus size. After three weeks, no
thrombus was detected and no systemic thromboembolic events had occurred.
Conclusions: The left ventricular apical thrombus resolved after dabigatran administration. Hence, dabigatran may
represent an alternative to warfarin as a therapeutic option in patients with previously detected intra-cardiac thrombus.
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In general, heparin and warfarin are used for the treat-
ment of intra-cardiac thrombi. Dabigatran is a novel oral
anti-coagulant that has recently been approved for use
in the prevention of thromboembolism in patients with
non-valvular atrial fibrillation. However, because of
limited dabigatran use in such situations, there are
relatively few reports in the literature regarding the
efficacy of dabigatran for the resolution of established
intra-cardiac thrombi. Herein described is the effectiveness
of dabigatran for thrombus resolution in a patient with a
left ventricular aneurysm.Case presentation
A 59-year-old Japanese man presented for treatment of
an intra-cardiac thrombus. At 52 years of age, he wasCorrespondence: 3kaku@nyc.odn.ne.jp
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reproduction in any medium, provided the ordiagnosed with mid-ventricular obstructive hypertrophic
cardiomyopathy (HCM) associated with paroxysmal atrial
fibrillation. Electrocardiography revealed poor R-wave pro-
gression at the V4 and V5 leads, and echocardiographic
images demonstrated asymmetrical septal hypertrophy and
mid-ventricular obstruction associated with paradoxical
diastolic flow (Figure 1). Although the global left ventricu-
lar ejection fraction was not markedly impaired, aneurysm
formation was observed at the left ventricular apex
(Figure 1), and technetium (99mTc) tetrofosmin single-
photon emission computed tomography demonstrated
severe hypoperfusion in this area (Figure 2). Coronary
angiography was concurrently performed, but revealed no
atherosclerotic lesions in the coronary arteries. At 55 years
of age, the patient developed sustained ventricular tachycar-
dia associated with hemodynamic collapse, for which an
implantable cardioverter-defibrillator (ICD) was inserted.
Although the administration of bisoprolol (5mg/day)
and amiodarone (200mg/day) were continued for thes is an open access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and














Figure 1 Echocardiographic images demonstrate asymmetrical septal hypertrophy and mid-ventricular obstruction associated with
paradoxical diastolic flow.
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ation, anti-coagulation therapy was not initiated because
no thrombus was detected on two echocardiographic
examinations of the patient at 52 and 55 years of age.
During the most recent echocardiographic examination,
however, an asymptomatic thrombus (15.0mm×17.0mm)
was detected in the apical aneurysm (Figure 3). Therefore,
hospital admission was recommended for anti-coagulation
therapy with continuous heparin infusion and warfarin
administration. However, because the patient obstinately
declined hospital admission and requested the continuation
of medical treatment at an ambulatory clinic, dabigatranadministration (150mg b.i.d.) was initiated. Coagulation
markers were measured before the commencement of anti-
coagulation therapy, and all were within the normal range
(Figure 4). Following dabigatran administration, an approxi-
mately two-fold increase in activated partial thromboplastin
time (measured four hours after dabigatran administration
with meals) was observed and the prothrombin time
internationalized ratio (PT-INR) was increased (Figure 4).
However, the levels of D-dimer, thrombin-anti-thrombin III
complex (TAT) and fibrinogen were not significantly
altered (Figure 4). Moreover, weekly echocardiographic
examinations demonstrated a gradual decrease in thrombus
Figure 2 Technetium-99m tetrofosmin single-photon emission
computed tomography scan demonstrates an area of severe
hypoperfusion at the left ventricular apex (arrows).
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one week after initial dabigatran administration showed
that thrombus size had decreased to 10.0mm×9.0mm.
Thrombus size had further decreased to 6.8mm×6.0mm
after two weeks, and no thrombus was detected after
three and four weeks. During the four-week treatment
period, no systemic thromboembolic events occurred.
Thus, the thrombus appears to have been resolved after
dabigatran administration. However, dabigatran administra-
tion was continued even after thrombus resolution.
Discussion
Mid-ventricular obstructive hypertrophic cardiomyopathy
is a rare form of HCM, accounting for approximately 5%
of all HCM cases [1]. However, it is sometimes associated
with apical aneurysms without significant atherosclerotic
coronary artery stenosis [2]. The annual incidence of
adverse cardiovascular events, including sudden death,
appropriate ICD discharges, thromboembolic stroke and
progressive heart failure, has been reported to be 10.5% in
patients with HCM-associated apical aneurysms [2].
Maron et al. reported the clinical courses of 28 patients
with HCM-associated apical aneurysms over a mean
follow-up period of 4.1±3.7 years, in which embolic stroke
or left ventricular apical thrombus was detected in four
patients [2]. On the basis of these results, they re-
commended prophylactic anti-coagulation therapy for the
prevention of embolic stroke in patients with apical
aneurysms. In the present case, no apical thrombus wasdetected on echocardiographic examinations of the
patient at 52 and 55 years of age, and anti-coagulation
therapy was not initiated. However, despite the patient’s
being asymptomatic, left ventricular apical thrombus was
detected on his echocardiographic examination performed
at 59 years of age.
Dabigatran is a reversible direct thrombin inhibitor which
has been approved for the prevention of thromboembolism
in patients with non-valvular atrial fibrillation [3] and in
those with thromboembolism after hip and knee replace-
ment surgeries [4]. Thrombin is a key factor in the coagu-
lant process because it converts fibrinogen into fibrin and
activates platelets and factors V, VII, VIII, IX and XIII.
Following oral administration, dabigatran etexilate is rapidly
hydrolyzed into dabigatran and subsequently absorbed
from the gastrointestinal tract. Dabigatran inactivates free
thrombin and fibrin-bound thrombin in a concentration-
dependent manner [5]. The efficacy and safety of dabigatran
for the prevention of stroke or systemic embolism in
patients with non-valvular atrial fibrillation was shown in
the Randomized Evaluation of Long-term Anticoagulation
Therapy trial [3]. In that trial, dabigatran administration at
110mg b.i.d. was associated with similar rates of
stroke and systemic embolism, but with a lower rate
of major bleeding than that associated with warfarin.
At 150mg b.i.d., dabigatran was associated with lower
rates of stroke and systemic embolism, but similar
rates of major bleeding, compared with those of warfarin.
Furthermore, the incidence of intra-cranial bleeding was
significantly lower during the anti-coagulation therapy
with both dabigatran doses compared with those of
warfarin. In patients with non-valvular atrial fibrillation, in
whom atrial thrombus was identified on transesophageal
echocardiography, the atrial thrombus was resolved by
four weeks of warfarin administration in approximately
80% to 90% of cases [6,7].
In contrast, the efficacy of the oral anti-coagulant
dabigatran in the resolution of previously detected
thrombus has not been extensively reported. Vidal et al.
[8] reported the first documented case of thrombus
resolution following dabigatran administration. In their
report, after dabigatran administration (150mg b.i.d.) for
eight weeks, a large left atrial appendage thrombus was
resolved with no concomitant thromboembolic events. In
the present case, on the basis of weekly echocardiographic
examinations, the size of the apical aneurysm thrombus
gradually decreased. After dabigatran administration for
three weeks, the apical aneurysm thrombus disappeared
without any thromboembolic events. The absence of
clinical events made migration of the thrombus an
unlikely explanation for its disappearance. Because plasma
levels of fibrinogen and TAT did not increase, systemic
coagulation activities did not increase, despite the




















































Figure 4 Serial changes in coagulation markers before and after anti-coagulation therapy with dabigatran (150mg b.i.d.). aPTT,
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Figure 3 Thrombic progression in apical aneurysm (thrombus indicated by arrows). (A) Prior to anti-coagulation therapy, thrombus size
was 15.0mm×17.0mm. (B) One week after initial dabigatran administration (150mg b.i.d.), thrombus size was 10.0mm×9.0mm. (C) Two weeks
after initial dabigatran administration (150mg b.i.d.), thrombus size was 6.8mm×6.0mm. (D) Three weeks after initial dabigatran administration
(150mg b.i.d.), thrombus was undetectable. (E) Four weeks after initial dabigatran administration (150mg b.i.d.), thrombus was still undetectable.
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D-dimer level, which is a fibrinolysis marker, did not
increase. After dabigatran administration, activated partial
prothrombin time was moderately prolonged and PT-INR
was slightly extended. These findings suggest that, in
situations in which dabigatran suppresses thrombin
activity without the activation of fibrinolysis, endogenous
fibrinolysis and the prevention of new thrombus for-
mation by dabigatran administration may be the pri-
mary mechanism of thrombus resolution. Some patients
showed resistance to anti-coagulation therapy with
warfarin [8], which also inhibits vitamin K-dependent
γ-carboxylation of proteins C and S. Therefore, warfarin
also has a potential thrombogenic effect by inhibiting the
activities of these anti-coagulant proteins. It was considered
that the initiation of warfarin therapy without the addition
of heparin at the ambulatory clinic may have triggered this
warfarin-induced proteins C and S paradox. Therefore,
dabigatran may present some advantages over warfarin.
The patient had the habit of ardently eating natto, a
traditional Japanese fermented soybean dish. Natto con-
tains a large quantity of vitamin K; thus, consumption of
even a small quantity of natto can strongly reverse the
effects of warfarin. Upon initiation of anti-coagulation
therapy with warfarin, patients must completely avoid
consuming vitamin K-rich foods such as natto. The
patient did not adhere to this suggestion, although he was
informed that the success of the treatment was dependent
on his not consuming natto. In contrast, dabigatran
efficacy is not limited by this type of food. If dabigatran
efficacy in the resolution of intra-cardiac thrombus can be
confirmed in other cases, dabigatran may represent an
alternative therapeutic option to warfarin in patients with
previously detected intra-cardiac thrombus.
Conclusions
Because thrombus resolution was successful in the present
case, dabigatran may have the potential to be used as
an alternative to warfarin in patients with established
intra-cardiac thrombus. However, additional cases are
needed to determine if dabigatran is effective for the
resolution of intra-cardiac thrombus.
Consent
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